当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Gastmeier Deja
Adverse drug reactions (ADRs) are a critical concern in veterinary medicine, impacting patient health and treatment outcomes. This paper explores the role of drug transporters in influencing ADRs in veterinary patients. Drug transporters are integral membrane proteins responsible for the movement of drugs into and out of cells, affecting drug disposition, efficacy, and safety. In veterinary medicine, understanding the interplay between drug transporters and ADRs is essential for optimizing drug therapy. This review highlights key drug transporters such as P-glycoprotein, multidrug resistanceassociated proteins, and organic anion transporters, emphasizing their significance in drug pharmacokinetics and disposition in various animal species. We discuss the impact of genetic variability in drug transporter genes on individual patient responses to medications, which can lead to variability in ADRs. Additionally, we examine the influence of drugdrug interactions on drug transporter function and its subsequent effects on ADRs. Furthermore, the paper discusses strategies for assessing drug transporter involvement in veterinary ADRs, including in vitro studies, pharmacogenomic approaches, and clinical monitoring techniques. These strategies can aid veterinarians in identifying patients at risk of ADRs and making informed treatment decisions.